De-fucosylated anti-spinous process protein antibody and application thereof
By developing the defucosylated anti-spinal protein antibody G2 S309, the serious problem of cytokine storm in SARS-CoV-2 infection was solved, and the production of IL-6 cytokines was significantly improved by activating monocytes and the treatment and The effect of prevention provides new methods for the diagnosis and treatment of the new coronavirus.
Patent Information
- Application Number
- CN202411036006.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-31
- Publication Date
- 2024-12-06
AI Technical Summary
The cytokine storm caused by SARS-CoV-2 infection seriously affects patients' health, the fucose modification model of existing antibodies affects their function and therapeutic effects, and lacks effective regulatory measures.
Developed a defucosylated anti-spinal protein antibody G2 S309 antibody whose Fc segment is engineered to partially or completely defucosylated, which can activate monocytes to produce IL-6 cytokines, thereby forming cells Factor storm, used to treat and prevent monocyte-mediated diseases.
By defucosylation of modified S309 antibodies, the activation ability of monocytes and IL-6 cytokine production is significantly improved, providing a new method to treat and diagnose cytokine storms, and improving the therapeutic effect of antibodies and the possibility of preventing complications.
Smart Images

Figure CN119080919A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biotechnology, and specifically relates to a defucosylated anti-spike protein antibody and an application thereof. Background Art
[0002] Clinical patients infected with SARS-CoV-2 mainly present with fever, cough, fatigue, and generalized muscle aches. Pathophysiological symptoms include dysregulated pulmonary perfusion, increased vascular permeability, and severe "cytokine storm". Severe cases may lead to acute respiratory distress syndrome (ARDS), multiple organ failure, and death.
[0003] SARS-CoV-2 is the seventh known coronavirus that can infect humans, and it is also the third global pandemic coronavirus after SARS-CoV and MERS-CoV. Through the study of the SARS-CoV-2 genome, the Coronavirus Research Group of the International Committee on Taxonomy of Viruses identified the virus as a homologous virus of SARS-CoV and named it SARS-CoV-2. The SARS-CoV-2 virus belongs to Beta coronavirus, an enveloped single-stranded RNA virus. The viral genome encodes 29 different proteins, including 4 major structural proteins: spike protein (S protein), envelope protein, membrane protein, and nucleocapsid protein. The S protein of SARS-CoV-2 consists of 1160 to 1400 amino acids, including an N-terminal signal peptide, a receptor binding fragment S1, and a fusion fragment S2. S1 is responsible for recognizing the receptor ACE2, and S2 is responsible for fixing the S protein on the cell membrane and mediating the fusion of the virus-host cell membrane.
[0004] Cytokine storm is a pathological state of excessive inflammation caused by a sudden increase in the levels of certain proinflammatory cytokines in the circulation, which leads to severe systemic inflammation, exacerbates viral pathogenesis, and causes sepsis, ARDS, and multiple organ failure. Cytokine storms are also seen in SARS, MERS, H5N1 influenza, and H7N9 influenza, as well as other respiratory viruses. Unlike the cytokine storm associated with SARS, the cytokine storm triggered by SARS-CoV-2 is associated with increased interleukin 4 (IL-4) and interleukin 10 (IL-10), which are anti-inflammatory cytokines released by Th2 cells. The total T cell count, CD4+T cell count, and CD8+T cell count in patients with severe SARS-CoV-2 infection were significantly lower than those in patients with mild disease. This suggests that COVID-19 patients have severe T cell loss, and progressive T cell exhaustion is associated with disease severity.
[0005] SARS-CoV-2 entry into cells depends on the binding of the S protein on the surface of the virus particles to the cell ACE2 receptor and the activation of the S protein by the host membrane serine protease (TMPRSS2). After SARS-CoV-2 enters the respiratory epithelial cells, it triggers an immune response, produces inflammatory cytokines, and is accompanied by a weak interferon response. The proinflammatory immune response of pathogenic Th1 cells and intermediate CD14+CD16+ monocytes is mediated by membrane-bound immune receptors and their downstream signaling pathways. Subsequently, macrophages and neutrophils infiltrate into the lung tissue, leading to a cytokine storm. In particular, SARS-CoV-2 can quickly activate pathogenic Th1 cells to secrete proinflammatory cytokines such as granulocyte-macrophage colony-stimulating factor (GM-CSF) and (IL-x). GM-CSF further activates CD14+CD16+ inflammatory monocytes to produce large amounts of interleukin 6 (IL-6), tumor necrosis factor-α (TNF-α), and other cytokines. Membrane-bound immune receptors may promote an unbalanced inflammatory response, and weak IFN-γ induction may be an important amplifier of cytokine production. The cytokine storm of COVID-19 is characterized by high expression of IL-6 and TNF-α. In addition, SARS-CoV-2 viral particles activate NF-κB through pattern recognition receptors. Studies have shown that SARS-CoV-2 enters through ACE2, leading to interruption of the Ang II pathway and ultimately causing cytokine release syndrome. Existing literature suggests that cytokine storms can aggravate symptoms of infection. Therefore, it is necessary to further study the cytokine storm in SARS-CoV-2, because cytokine storms occur in critically infected patients, and inhibiting cytokine storms may prevent symptom deterioration and help clinicians prolong patient life.
[0006] Severe COVID-19 patients show severe inflammatory features, including high levels of inflammatory factors, alveolar inflammatory infiltration, and cytokine storm. Analysis of patients' sera revealed that severe patients had unique serological characteristics, including an increase in IgG1 with defucosylation of the Fc segment. Defucosylation of the IgG1 Fc segment enhances its interaction with activated FcγRⅢa; when incorporated into immune complexes, the defucosylated Fc segment stimulates monocytes to produce inflammatory cytokines, including IL-6 and tumor necrosis factor. In general, the severity of COVID-19 disease is associated with fucosylation modification of the IgG Fc structure.
[0007] At present, there are defucosylated monoclonal antibodies on the market, such as Mogamulizumab from Kirin Pharmaceutical Co., Ltd., which was approved for marketing in Japan in 2012. It is a humanized monoclonal antibody targeting CCR4 and its main indications are severe blood diseases. Glycosylation modification has an important influence on the efficacy, stability, immunogenicity, and pharmacokinetic properties of monoclonal antibody drugs, so glycosylation modification is considered to be a key quality attribute of monoclonal antibody drugs. According to the mechanism of action of antibodies, researchers have targetedly optimized the glycosylation structure and level in antibody molecules, such as improving ADCC activity by knocking out fucose, in order to achieve the purpose of developing higher effectiveness, safety, or improving pharmacokinetics.
[0008] In the field of antibody research, fucose modification of antibodies is also considered an important factor affecting their biological functions. Studies have shown that in SARS-CoV-2 infection, fucose modification of antibodies will affect their neutralization of the virus; in cytokine storms, defects in glycosylation modification of antibodies will also affect their ability to regulate immune cells; in SARS-CoV-2 infection, antibodies as the main component of the immune mechanism are affected by fucose modification. Studies have shown that many specific antibodies are highly dependent on affinity-based fucose modification when binding to the spike protein of the new coronavirus. Antibodies with incomplete fucose modification may lose their efficient neutralization effect, thereby affecting the diagnosis and treatment of the disease.
[0009] In summary, fucose modification and modification defects have an important impact on the function of antibodies, and different modification patterns have multi-level effects on the activity, efficacy, specificity, etc. of antibodies. In response to SARS-CoV-2 infection and cytokine storm, the production and application of antibodies will be directly affected by factors such as the quality, stability and proportion of fucose modification. Therefore, while optimizing antibody research and treatment, it is necessary to pay attention to and strengthen the regulation and research of antibody fucose modification to improve the therapeutic effect and prevent the possibility of complications. Summary of the invention
[0010] The main purpose of the present invention is to provide a defucosylated anti-spike protein antibody, which is a S309 antibody variant - G2 S309 antibody, whose Fc segment is modified to be partially or completely defucosylated, which can cause monocyte activation and increase the IL-6 cytokine secreted by monocytes, thereby forming a cytokine storm.
[0011] Another object of the present invention is to provide an application of the defucosylated anti-spike protein antibody, for example, for preparing a drug for treating and / or preventing diseases mediated by monocytes and / or caused by abnormal monocytes.
[0012] To achieve the above object, the present invention adopts the following technical solution:
[0013] The present invention provides a defucosylated anti-spike protein antibody, which is a G2 S309 antibody obtained by transforming the S309 IgG monoclonal antibody, wherein the Fc segment of the G2 S309 antibody is defucosylated.
[0014] Preferably, after the G2 S309 antibody and S protein form an antigen-antibody complex, monocytes can be activated to produce IL-6 cytokines, thereby forming a cytokine storm.
[0015] Preferably, the G2 S309 antibody or antigen-binding portion thereof exhibits one or more of the following properties A)-D):
[0016] A) Binding to SARS-CoV-2;
[0017] B) Binds to the spike protein (S protein) on SARS-CoV-2;
[0018] C) activated human peripheral blood mononuclear cells;
[0019] D) activates human peripheral blood mononuclear cells and causes an increase in the concentration of IL-6 cytokines, forming a cytokine storm.
[0020] Preferably, the Fc segment of the G2 S309 antibody is partially defucosylated, wherein the defucosylation ratio is not less than 16%.
[0021] More preferably, the Fc segment of the G2 S309 antibody is completely defucosylated.
[0022] The present invention also provides the use of the defucosylated anti-spike protein antibody in the preparation of a product or drug having at least one of the following functions I)-III):
[0023] Ⅰ) Binds to the spike protein (S protein) on SARS-CoV-2;
[0024] Ⅱ) Activate human peripheral blood mononuclear cells;
[0025] III) Treating and / or preventing diseases mediated by monocytes and / or caused by abnormal monocytes.
[0026] Preferably, the concentration of the defucosylated anti-spike protein antibody is not less than 0.1 μg / mL.
[0027] Compared with the prior art, the present invention has the following beneficial effects:
[0028] The present invention proposes an artificially modified anti-spike protein antibody S309. By preparing S309 monoclonal antibodies with core fucosylation modification and S309 monoclonal antibodies completely lacking core fucosylation modification, it is found through monocyte stimulation experiments that S309 monoclonal antibodies completely lacking core fucosylation modification are more likely to cause cytokine storms. In addition, the present invention also establishes an in vitro monocyte stimulation experiment, which can be used as a method for detecting cytokine storms. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1 The glycan profile of the S309 monoclonal antibody expressed by 293 wild-type cells in Example 1 is shown.
[0030] Figure 2 Figure 2 shows the glycan profile of the S309 monoclonal antibody expressed in 293 cells (293-FUT8 KO) in which fucosyltransferase 8 (FUT8) was knocked out in the examples.
[0031] Figure 3 Schematic diagram of artificially modifying the S309 monoclonal antibody to prepare the G2F S309 antibody in the examples.
[0032] Figure 4 This is a mass spectrometry analysis of the G2F S309 antibody after glycoengineering in the example.
[0033] Figure 5 This is a mass spectrometry analysis of the G2 S309 antibody after glycoengineering in the example.
[0034] Figure 6 The results are shown in the examples below for the effects of different ratios of the G2 S309 antibody on monocyte stimulation. DETAILED DESCRIPTION
[0035] In order to more fully understand and demonstrate the technical solutions, purposes and advantages of the present invention, the technical effects produced by the present invention are further described in detail and completely in conjunction with specific embodiments. Obviously, the described embodiments are only part of the embodiments of the present invention, not all. It should be pointed out that for those of ordinary skill in the art, other embodiments obtained without departing from the concept of the present invention all belong to the protection scope of the present invention.
[0036] 1. Modification of S309 antibody
[0037] 1.1 Glycan analysis of S309 monoclonal antibody expressed in WT and FUT8 KO cells
[0038] Glycan analysis of S309 monoclonal antibody expressed in two different cells, such as Figure 1 and 2As shown, the results showed that the glycan spectrum of the S309 monoclonal antibody expressed by 293 wild-type cells still had 5% defucosylated IgG1, and the glycoform analysis of the S309 monoclonal antibody expressed by 293 cells with FUT8 knocked out did not contain the three glycoforms G0F, G1F, and G2F, but only the three glycoforms G0, G1, and G2, indicating the absence of core fucosylation modification.
[0039] 1.2G2F S309 antibody preparation
[0040] The process for preparing G2F S309 antibody is as follows Figure 3 As shown, 500 μg of wild-type S309 antibody (final concentration 3.5 mg / mL) and 0.2 mg / mL of Fc BP2-PEG8-MCC-D165A were mixed and incubated at 37°C for 24 hours to hydrolyze the antibody N-sugar chain. After the hydrolysis was completed, 1 mM CT-ox and 0.1 mg / mL Fc BP2-PEG8-MCC-D165A were added in sequence. After reacting at 30°C for 2.5 hours, 0.25 mM CT-ox was added and the reaction continued for 0.5 hours. LC-MS identified the generation of CT-S309 (i.e., G2F S309) with a main content of +2. The enzyme and unreacted sugar substrate were removed by purification using a Protein-A affinity chromatography column. The purified product was analyzed by mass spectrometry as shown below. Figure 4 shown.
[0041] 1.3G2 S309 antibody preparation
[0042] 5mg / mL wild-type S309 antibody, 0.05mg / mL Endo S2-D184M and 0.3mg / mL Alfc were added to 50mM PB buffer at pH 6.5 in sequence, mixed and incubated at 37°C for 6h, and after LC-MS confirmed that they were all converted into desugared antibody GlcNAc-S309 (GN-S309), they were purified by Protein A affinity chromatography column. Then, 5mg / mL GlcNAc-S309 and 1.5mM CT-ox were added to pH 7.4, 50mM PB buffer in sequence, the solution pH was adjusted to about 7.4, 0.15mg / mL Endo S2-D184M was added, and incubated at 30°C for 4h. After LC-MS confirmed that it was basically converted into G2 S309, it was purified by Protein A, and the purified product was analyzed by mass spectrometry as shown in FIG. Figure 5 shown.
[0043] 2. Isolation of human peripheral blood mononuclear cells (PBMC)
[0044] 2.1 Isolation of mononuclear cells
[0045] (1) Collect human peripheral blood: collect blood using anticoagulant tubes or use defibrinated peripheral blood.
[0046] (2) Dilution of peripheral blood: Sterile PBS and peripheral blood were diluted 1:1 (v / v).
[0047] Prepare the separation system: human PBMC separation solution in a 50 mL centrifuge tube Diluted peripheral blood = 1:2 (v / v). First add human PBMC separation solution (Cedarlane, CL5020), use a pipette to draw diluted peripheral blood, add drop by drop along the wall of the tube, so that the peripheral blood is spread evenly on the surface of the separation solution, and the two solutions can be seen slightly mixed at the interface (Note: sterile operation, let the blood slowly spread on the surface of the separation solution).
[0048] (3) Centrifugation: room temperature, 800 g, 20 min, acceleration 5, acceleration 1. A cloudy layer is visible after centrifugation, which is the mononuclear cell layer.
[0049] (4) Transferring monocytes: Gently aspirate the monocyte layer with a pipette tip and transfer it to a new 15 mL centrifuge tube.
[0050] (5) Washing: Add 3 times the volume of sterile PBS to the transferred monocytes, gently pipette, centrifuge at 1500 rpm for 5 min, repeat three times, resuspend in PBS and count, add an equal volume of bromophenol blue solution to count live and dead cells.
[0051] 2.2 Isolation of monocytes
[0052] Monocytes were isolated using the Easysep™ human monocyte isolation kit from Stemcell.
[0053] (1) Dilute human PBMC to 5 × 10^7 cells / mL with PBS, filter with a 40 μm filter to remove the cell precipitate, take 2 mL of the cell suspension, and transfer it to a flow tube.
[0054] (2) Place the flow tube on a rack, add 100uL (50μL / mL) of Isolation Cocktail, and let stand at room temperature for 5 min.
[0055] (3) Vortex the magnetic particles for 30 seconds.
[0056] (4) Add magnetic particles to the sample, mix and incubate at 50 μL / mL for 10 min at RT.
[0057] (5) Add medium solution (PBS containing 2% fetal bovine serum (FBS) and 2% 0.5 M ethylenediaminetetraacetic acid (EDTA)), fill the sample to 2.5 mL, and gently pipette up and down 2-3 times to mix.
[0058] (6) Place the flow tube (without the lid) in a magnet for incubation and leave at room temperature for 5 min.
[0059] (7) Pick up the magnet and invert the magnet and test tube in one continuous motion to pour the enriched cell suspension into a new test tube.
[0060] (8) Repeat steps 6-7.
[0061] The harvested suspension is the isolated mononuclear cells, which are stained for live and dead cells and counted.
[0062] 3. Preparation of antigen-antibody complex
[0063] The S309 antibody and the S trimer protein (Spike protein) were mixed at a molar ratio of 30:1 to prepare the immune complex, and the trimer protein was calculated according to n = m / M. Specifically, the relative molecular mass of the G2 S309 and G2F S309 antibodies is 150 KDa, the relative molecular mass of the Spike protein is 146.6 KDa, and M 抗体 / 150:M S蛋白 / 146.6=30:1, when the antibody is 1μg, the mass of the Spike protein is 0.0326μg. The Spike protein used comes from the most original strain of SARS-CoV-2, and the original concentration is 1.66mg / mL.
[0064] 3.1 Incubation of single antibody and antigen
[0065] Take G2 S309 and G2F S309 antibodies and dilute them with 1640 medium to 0.2, 0.4, 0.8, 2, 4, 8, 20 μg / mL, 200 μL for each concentration. Dilute Spike protein to 0.00652 μg / mL, 0.01304 μg / mL, 0.02608 μg / mL, 0.0652 μg / mL, 0.1304 μg / mL, 0.2608 μg / mL, 0.652 μg / mL, and prepare 250 mL. Take 100 μL of each concentration of antibody and 100 μL of the corresponding concentration of Spike protein, mix, and incubate at 37°C for 1 hour.
[0066] 3.2 Incubation of different ratios of G2 S309 and G2F S309 mixtures with antigens
[0067] G2 S309 / G2F S309 antibodies were mixed at a concentration of 2 μg / mL at a ratio of 0%, 1%, 2%, 4%, 8%, 16%, 32%, 64%, and 100%. G2 S309 and G2F S309 antibodies were diluted to 4 μg / mL with 1640 culture medium, 200 μL; Spike protein was diluted to 0.1304 μg / mL and 1 mL was prepared. 4 μg / mL of G2 S309 and G2F S309 antibodies were mixed to a ratio of G2S309 / G2F S309 = 0%, 1%, 2%, 4%, 8%, 16%, 32%, 64%, and 100%. 100 μL of antibodies at various ratios at a concentration of 4 μg / mL and 100 μL of 0.1304 μg / mL Spike protein were mixed. Only 100 μL of 1640 culture medium and 100 μL of Spike protein were added to the control wells, and incubated at 37°C for 1 h.
[0068] 4. Co-culture of complexes and monocytes
[0069] To avoid the co-culture system being too large, the monocytes were diluted to 2×10^7 / mL with 1640 medium, and 10μL / well was plated on a 96-well round-bottom plate for culture. The cells were cultured under 5% CO2 for 15 minutes, and then 100uL / well of antigen-antibody immune complex was added. The cells were co-cultured for 18 hours. The cells were then centrifuged at 1500rpm for 5 minutes, and the supernatant was taken to detect the IL-6 concentration.
[0070] 5. IL-6 concentration detection
[0071] IL-6 concentration was detected using an IL-6 ELISA kit from biolegend. 12.5 μL of the standard stock solution was diluted into 487.5 μL of assay buffer A to prepare 500 μL of 500 pg / mL highest standard. Using assay buffer A as the diluent, the 500 pg / mL highest standard was diluted 6 times in different tubes by 2-fold. The standard concentrations of human IL-6 were 500 pg / mL, 250 pg / mL, 125 pg / mL, 62.5 pg / mL, 31.3 pg / mL, 15.6 pg / mL, and 7.8 pg / mL, respectively, with assay buffer A as the zero standard (0 pg / mL).
[0072] Wash each well 4 times with 300 μL of 1× wash buffer and invert the washed plate and tap it firmly on absorbent paper to remove any remaining buffer. All subsequent washes should be performed in a similar manner. Add 50 μL of assay buffer A, which includes standard diluents or samples, to each well, add 50 μL of standard diluents or samples to the appropriate wells, seal the plate and incubate the plate for 2 h at room temperature while shaking at 200 rpm.
[0073] Pour the contents of the plate into the sink, then wash the plate four times with 1× wash buffer, add 100 μL of human IL-6 detection antibody solution to each well, seal the plate, and incubate at room temperature with shaking for 1 h.
[0074] Pour the contents of the plate into the sink, then wash the plate four times with 1× wash buffer, add 100 μL of avidin-horseradish peroxidase A solution to each well, seal the plate, and incubate at room temperature with shaking for 30 min.
[0075] Pour the contents of the plate into the sink, then wash the plate 5 times with 1x wash buffer, add 100 μL of substrate solution F to each well, and incubate for 15 min in the dark. Wells containing human IL-6 should appear blue, with an intensity proportional to the concentration, and it is not necessary to seal the plate at this step.
[0076] Add 100 μL of stop solution to each well to stop the reaction. The color of the solution changes from blue to yellow. Read the absorbance at 450 nm and 570 nm within 30 min. Subtract the absorbance at 570 nm from the absorbance at 450 nm when processing the data.
[0077] 6. Experimental results
[0078] Different ratios of G2 S309 antibody and G2F S309 antibody were mixed. It can be seen that when the ratio of G2 S309 antibody was 16%, monocytes were significantly activated, such as Figure 6 As shown in the figure, G2 S309 antibody can activate monocytes more than G2F S309 antibody. When G2 S309 antibody is at 0.1 μg / mL, the concentration of IL-6 is significantly increased, which means that defucosylation modification is related to the inflammatory factor storm in patients with severe pneumonia.
[0079] In summary, from the perspective of glycobiology, the present invention experimentally proves the relationship between fucose modification on IgG antibodies and monocyte stimulation. The results show that the S309 monoclonal antibody with complete fucose has a weak ability to activate monocytes, while the S309 with core fucose deficiency has a stronger ability to activate monocytes. The lowest concentration of G2 S309 antibody that causes monocyte stimulation (0.1 μg / mL) and the ratio of fucose deficiency required to activate monocytes (16%) were determined for the first time. When the G2S309 antibody was at 0.1 μg / mL, the concentration of IL-6 increased significantly; when the proportion of G2 S309 antibody in the total S309 monoclonal antibody reached 16%, it could cause a surge in IL-6, thereby causing a cytokine storm, laying the foundation for the establishment of an accurate new crown diagnosis method.
[0080] The above are only preferred embodiments of the present invention and are not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A defucosylated anti-spike protein antibody, characterized in that: The anti-spike protein antibody is a G2 S309 antibody transformed from the S309 IgG monoclonal antibody, wherein the Fc segment of the G2 S309 antibody is defucosylated.
2. The defucosylated anti-spike protein antibody according to claim 1, characterized in that After the G2 S309 antibody and S protein form an antigen-antibody complex, they can activate monocytes to produce IL-6 cytokines, thereby forming a cytokine storm.
3. The defucosylated anti-spike protein antibody according to claim 1, characterized in that: The Fc segment of the G2 S309 antibody is partially defucosylated, wherein the defucosylation ratio is not less than 16%.
4. The defucosylated anti-spike protein antibody according to claim 3, characterized in that: The Fc region of the G2 S309 antibody is completely defucosylated.
5. The defucosylated anti-spike protein antibody according to any one of claims 1 to 4, characterized in that The G2S309 antibody or antigen-binding portion thereof exhibits one or more of the following properties A)-D): A) Binding to SARS-CoV-2; B) Binds to the spike protein on SARS-CoV-2; C) activated human peripheral blood mononuclear cells; D) activates human peripheral blood mononuclear cells and causes an increase in the concentration of IL-6 cytokines, forming a cytokine storm.
6. Use of the defucosylated anti-spike protein antibody according to any one of claims 1 to 5 in the preparation of a product or drug having at least one of the following functions I) to III): Ⅰ) Binds to the spike protein on SARS-CoV-2; Ⅱ) Activate human peripheral blood mononuclear cells; III) Treating and / or preventing diseases mediated by monocytes and / or caused by abnormal monocytes.
7. The use according to claim 6, characterized in that: The concentration of the defucosylated anti-spike protein antibody is not less than 0.1 μg / mL.
